Advertisement
Canada markets close in 3 hours 24 minutes

  • S&P/TSX

    21,842.92
    -30.80 (-0.14%)
     

  • S&P 500

    5,028.69
    -42.94 (-0.85%)
     

  • DOW

    37,990.78
    -470.14 (-1.22%)
     

  • CAD/USD

    0.7307
    +0.0009 (+0.12%)
     

  • CRUDE OIL

    82.57
    -0.24 (-0.29%)
     

  • Bitcoin CAD

    87,677.17
    -660.45 (-0.75%)
     

  • CMC Crypto 200

    1,384.96
    +2.38 (+0.17%)
     

  • GOLD FUTURES

    2,338.80
    +0.40 (+0.02%)
     

  • RUSSELL 2000

    1,970.75
    -24.67 (-1.24%)
     

  • 10-Yr Bond

    4.7100
    +0.0580 (+1.25%)
     

  • NASDAQ

    15,514.97
    -197.78 (-1.26%)
     

  • VOLATILITY

    16.44
    +0.47 (+2.94%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6811
    -0.0008 (-0.12%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

Five Star Equities Issues New Research Reports on ABTL, DRNA, MYGN and RNN

ACCESSWIRE

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Autobytel Inc. (NASDAQ:ABTL - News) shares surged 25.44 percent to close at $15.09 a share Wednesday. The stock traded between $12.83 and $15.25 on volume of 1.12 million shares traded. The company now expects year-over-year total revenue growth, including AutoUSA, of 45 percent to 47 percent for the first quarter of 2014. Shares of Autobytel are down approximately 0.25 percent year-to-date.

Get more information on Autobytel and free access to the in-depth equity report at:
www.FiveStarEquities.com/ABTL

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA - News) shares declined 4.90 percent to close at $25.21 a share Wednesday. The stock traded between $23.77 and $27.22 on volume 363,290 shares traded. The company previously reported a net loss of 6.7 million for the fourth quarter of 2013, compared to a net income of $10.1 million a year ago. Shares of Dicerna Pharmaceuticals are down approximately 45.0 percent year-to-date.

ADVERTISEMENT

Get more information on Dicerna Pharmaceuticals free access to the in-depth equity report at:
www.FiveStarEquities.com/DRNA

Myriad Genetics, Inc. (NASDAQ:MYGN - News) shares soared 11.47 percent to close at $39.18 a share Wednesday. The stock traded between $39.10 and $40.33 on volume of 7.50 million shares traded. The Centers for Medicare and Medicaid Services will now reimburse 37.0 percent more for its gene-based tests for breast cancer. Shares of Myriad Genetics are up approximately 87.0 percent year-to-date.

Get more information on Myriad Genetics and free access to the in-depth equity report at:
www.FiveStarEquities.com/MYGN

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN - News) shares spiked 12.28 percent to close at $1.28 a share Wednesday. The stock traded between $1.16 and $1.25 on volume 9.66 million shares traded. The company announced that it would present data on RX-3117 and RX-21101 at the 2014 American Association for Cancer Research Annual Meeting. Shares of Rexahn Pharmaceuticals are up approximately 150.0 percent year-to-date.

Get more information on Rexahn Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/RNN

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com